Infectious Vaccines Partnering - Market Terms and Agreements

299 views
212 views

Published on

Infectious Vaccines Partnering Market @ http://www.researchmoz.us/infectious-vaccines-partnering-terms-and-agreements-report.html

The Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
299
On SlideShare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Infectious Vaccines Partnering - Market Terms and Agreements

  1. 1. Infectious Vaccines Partnering Terms and Agreements The Infectious Vaccines Partnering Terms and agreements report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances. This report provides details of the latest infectious vaccines agreements announced in the healthcare sectors. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all infectious vaccines partnering deals announced since January 2007, including financial terms where available, including over 700 links to online deal records of actual infectious vaccines partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following: What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report provide an orientation of infectious vaccines dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst Chapter 2 provides an overview of the trends in infectious vaccines dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading infectious vaccines deals since 2007. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 big pharma companies for which deals are available, with a brief summary followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive listing of the big biotech companies for which deals are available, with a brief summary followed by a comprehensive listing of infectious vaccines deals, as well as contract documents available in Infectious Vaccines Partnering Terms and Agreements
  2. 2. the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. Chapter 6 provides a comprehensive and detailed review of infectious vaccines partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in infectious vaccines partnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of infectious vaccines technologies and products.. Report scope Infectious Vaccines Partnering Agreements is intended to provide the reader with an in-depth understanding and access to infectious vaccines trends and structure of deals entered into by leading companies worldwide. Infectious Vaccines Partnering Agreements includes: Trends in infectious vaccines dealmaking in the biopharma industry since 2007 Analysis of infectious vaccines deal structure Access to headline, upfront, milestone and royalty data Access to over 700 infectious vaccines deal records The leading infectious vaccines deals by value since 2007 Includes adjuvant deals and alliances since 2007 In Infectious Vaccines Partnering Agreements, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific infectives therapy target Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. table Of Contents executive Summary chapter 1 – Introduction chapter 2 – Trends In Infectious Vaccines Dealmaking 2.1. Introduction 2.2. Infectious Vaccines Partnering Over The Years 2.3. Big Pharma Infectious Vaccines Dealmaking Activity 2.4. Big Biotech Infectious Vaccines Dealmaking Activity 2.4. Most Active In Infectious Vaccines Partnering 2.5. Infectious Vaccines Partnering By Deal Type 2.6. Infectious Vaccines Partnering By Stage Of Development 2.7. Infectious Vaccines Partnering By Infectives Indication 2.8. Infectious Vaccines Partnering By Vaccine And Adjuvant Indication 2.9. Disclosed Deal Terms For Infectious Vaccines Partnering Infectious Vaccines Partnering Terms and Agreements
  3. 3. 2.9.1 Infectious Vaccines Partnering Headline Values 2.9.2 Infectious Vaccines Deal Upfront Payments 2.9.3 Infectious Vaccines Deal Milestone Payments 2.9.4 Infectious Vaccines Royalty Rates 2.10. The Anatomy Of Infectious Vaccines Partnering 2.10. The Anatomy Of A Infectious Vaccines Deal 2.10.a. Case Study 1: Gilead Sciences, Globeimmune- Oct 24 2011 2.10.b. Case Study 2: Astellas, Vical: July 14, 2011 chapter 3 – Leading Infectious Vaccines Deals 3.1. Introduction 3.2. Top Infectious Vaccines Deals By Value chapter 4 – Bigpharma Infectious Vaccines Deals 4.1. Introduction 4.2. How To Use Bigpharma Partnering Deals 4.3. Big Pharma Infectious Vaccines Partnering Company Profiles abbott astellas astrazeneca baxter International bayer csl daiichi Sankyo eisai gilead Sciences glaxosmithkline johnson & Johnson kyowa Hakko Kirin merck & Co mitsubishi Tanabe novartis pfizer roche sanofi shionogi takeda chapter 5 – Big Biotech Infectious Vaccines Deals 5.1. Introduction Infectious Vaccines Partnering Terms and Agreements
  4. 4. 5.2. How To Use Big Biotech Partnering Deals 5.3. Big Biotech Infectious Vaccines Partnering Company Profiles bavarian Nordic cangene emergent Biosolutions chapter 6 – Infectious Vaccines Dealmaking Directory 6.1. Introduction 6.2. Company A-z 3m a*star Agency For Science, Technology And Research a*star Bioprocessing Technology Institute a*star Singapore Immunology Network aaron Diamond Aids Research Center abbott Laboratories aberystwyth University absynth Biologics academia Sinica acambis accelovance ace Biosciences achaogen adimmune aduro Biotech advanced Bionutrition advanced Bioscience Laboratories advanced Immunization Technologies (aditec) advaxis aeras Global Tb Vaccine Foundation affiris agenus Bio agilent Technologies ajanta Pharma akorn akshaya Bio albany Medical College albert Einstein College Of Medicine aldevron alexis Biotech algonomics alk-abello allied Healthcare Group Infectious Vaccines Partnering Terms and Agreements
  5. 5. alnylam Pharmaceuticals alphavax althea Technologies altravax american Type Culture Collection (atcc) amvac amyris Biotechnologies anc Bio anges Mg antelope Valley Biologics antigen Discovery antigen Express antigenics antitope apogee Biotechnology apotex archimedes Development archimedes Pharma arecor argos Therapeutics ariad Pharmaceuticals ariavax arizona State University ark Therapeutics artepharm Co artepharm Global artes Biotechnology astellas Pharma astellas Pharma Us astrazeneca astrogenetix atreca australian Centre For Vaccine Development australian National University avac avant Immunotherapeutics avecia Biologics avi Pharma avid Bioservices avimex barr Pharmaceuticals battelle bavarian Nordic Infectious Vaccines Partnering Terms and Agreements
  6. 6. baxter International bayer beijing Health Bureau beijing Tiantan Biological Products beth Israel Deaconess Medical Center biken bill And Melinda Gates Foundation binnopharm bio-manguinhos bioalliance Pharma biocryst Pharmaceuticals biodiem biofactura bioject Medical Technologies biolik Biopharmaceutical biological E biomedical Advanced Research And Development Authority biondvax bioniche Life Sciences bionor Pharma biopharm Services bioreliance biota biotechnology And Biological Sciences Research Council (bbsrc) bioveris biovest birmex boryung Pharmaceutical brigham Young University butantan Institute cadila Pharmaceuticals cambridge Biostability cangene capsulation Nanoscience carrington Laboratories case Western Reserve University catherex catholic University Of America celldex Therapeutics cellectis Bioresearch centegen centers For Disease Control And Prevention centre National De Recherche Et De Formation Sur Le Paludisme Infectious Vaccines Partnering Terms and Agreements
  7. 7. centro De Investigacion Y Asistencia Tecnologica Y Diseno Del Estado De Jalisco centrovet centrovet Laboratories ceva Sante Animale cevec Pharmaceuticals changchun Bcht Biotechnology chemrar High-tech Center chengdu Institute Of Biological Products cheyney University china Centre For Disease Control china National Biotech Group (cnbg) chinese Center For Disease Control And Prevention chinese Federal Government chongqing Zhifei Biological Products chrontech Pharma chumakov Institute Of Poliomyelitis And Viral Encephalitides clintec International cobra Biologics coley Pharmaceutical Group colorado Institute For Drug, Device And Diagnostic Development compass Biotechnologies corgenix Medical cpl Biologicals critical Path Institute (c-path) crossbeta Biosciences crucell crucible International Biotechnologies csiro csl csl Biotherapies curevac cytodyn cytogenix cytos Biotechnology cyvax daiichi Pharmaceutical daiichi Sankyo dalton Pharma Services dana-farber Cancer Institute danish Defence dartmouth College dbv Technologies defence Research And Development Canada Infectious Vaccines Partnering Terms and Agreements
  8. 8. defense Advanced Research Projects Agency defense Threat Reduction Agency defyrus delphi Genetics delsite department Of Defense department Of Health And Human Services department Of Homeland Security diagnostic Hybrids dor Biopharma drexel University dri Capital drugs For Neglected Diseases Initiative duke-nus Graduate Medical School Singapore duke University duke University Medical Center dynavax Technologies dynport Vaccine Company eden Biodesign eisai elanco emcure Pharmaceuticals emd Millipore emergent Biosolutions emergent Product Development emory University encorium Group endobiologics enwave epic Bio epicept epitopix erasmus University Medical Center esteve european Commission european Union european Vaccine Initiative evolutec evolva exploit Technologies expres2ion Biotechnologies fabentech fina Biosolutions Infectious Vaccines Partnering Terms and Agreements
  9. 9. fit Biotech flugen food And Drug Administration (fda) formatech fort Dodge Animal Health fourth Military Medical University fraunhofer Usa fraunhofer Usa Center For Molecular Biotechnology french National Institute For Agricultural Research french National Research Agency fusion Ip g-con gador gamma Vaccines ge Healthcare geneart generex Biotechnology genethera genetic Immunity genocea Biosciences genomidea genphar genvec geovax german Cancer Research Center gilead Sciences glaxosmithkline glaxosmithkline Biologicals glide global Green globeimmune glycomimetics glycosensors And Diagnostics glycovaxyn gni goodwin Biotechnology government Of Canada government Of China government Of India government Of Japan government Of United Kingdom green Cross harbin Pharmaceutical Group Infectious Vaccines Partnering Terms and Agreements
  10. 10. harrisvaccines harvard Medical School harvard University hawaii Biotech health Protection Agency (hpa) heat Biologics helmholtz Centre For Infection Research hemispherx Biopharma henderson Morley henry Schein hiv Vaccine Trials Network (hvtn) hollister-stier Labs hunan Biopharmaceutical ibio ibiopharma ichor Medical Systems icon Genetics id Biomedical ihi ihi Plant Engineering Corporation imaxio immbio immune Design immuneregen Biosciences immunomedics immunovaccine immunovaccine Technologies imperial Innovations imugene in Cell Art inclinix infectious Disease Research Institute (idri) inovio Biomedical inovio Pharmaceuticals inserm institut Pasteur institute For Medical Microbiology, Immunology And Hygiene (immih) institute For Oneworld Health integrated Biopharma integrated Biotherapeutics intercell international Aids Vaccine Initiative international Center For Genetic Engineering And Biotechnology Infectious Vaccines Partnering Terms and Agreements
  11. 11. international Medica Foundation international Vaccine Institute (ivi) intervet inviragen invitria iomai ippox Foundation iq Products iqur irsicaixa Aids Research Institute isconova istituto Superiore Di Sanita italian Government janssen Pharmaceutica Nv janssen Pharmaceutical jantibody Therapeutics japan Government jenner Institute jiangsu Walvax johns Hopkins University johnson & Johnson jsc Binnopharm juvaris Biotherapeutics kaketsuken karolinska Institute kirin Pharma kitasato Daiichi Sankyo Vaccine kitasato Institute kyoto Biken kyowa Hakko Kirin la Jolla Institute For Allergy & Immunology lallemand Pharma Europe lebanese-canadian Hospital leiden University leidos Holdings lentigen lg Life Sciences ligocyte Pharmaceuticals lipotek lipoxen liquidia Technologies lohmann Animal Health lonza Infectious Vaccines Partnering Terms and Agreements
  12. 12. lovelace Respiratory Research Institute lucigen mahidol University maryland Technology Development Corporation massachusetts Biologic Laboratories massachusetts General Hospital massbiologics max-planck max Planck Institute For Dynamics Of Complex Technical Systems maxcyte maxygen mayo Clinic mcmaster University medicago medicine In Need medicines For Malaria Venture medigene medimmune medison Pharma mellow Hope Bio Chem merck And Co merial meridian Bioscience meridian Life Science merix Bioscience metabolon microbix Biosystems military Hiv Research Program (mhrp) ministry Of Defence ministry Of Health Of Brazil mitsubishi Tanabe Pharma mologen monash University monosol Rx mount Sinai School Of Medicine mpi Research msd Wellcome Trust Hilleman Laboratories mucosis mymetics nabi Biopharmaceuticals nanobio nanotherapeutics nanoviricides Infectious Vaccines Partnering Terms and Agreements
  13. 13. narvac nasa nasvax national Cancer Institute national Health And Medical Research Council national Healthcare Services (nhs) national Institute Of Allergy And Infectious Diseases national Institute Of Infectious Diseases national Institute Of Nanotechnology national Institute On Drug Abuse (nida) national Institutes Of Health national Microbiology Laboratory national Research Council Canada national University Of Singapore naval Medical Research Center navy Medical Research Centre netherlands Vaccine Institute neugenesis new York Medical College niigata Tlo/nbrp/kutlo-nitt ninebio ninesigma nobilon noguchi Memorial Institute For Medical Research north West Fund novartis novartis Vaccines novation novavax novozymes numerate nuron Biotech nyu Langone Medical Center omnia Biologics omnivest opal Therapeutics opko Health opsona Therapeutics ortho-mcneil-janssen Pharmaceuticals ortho-mcneil oseo oswaldo Cruz Foundation oswaldo Cruz Foundation (fiocruz) Infectious Vaccines Partnering Terms and Agreements
  14. 14. oxford- Emergent Tuberculosis Consortium oxford Biomedica pacificgmp paladin Labs pan-provincial Vaccine Enterprise pan American Health Organization paragon Bioservices parenteral Biotech path (appropriate Technology In Health) path Malaria Vaccine Initiative paxvax pecet pediatric Dengue Vaccine Initiative pennsylvania Department Of Health pepscan Therapeutics peptcell peptimmune peptivir pevion pfenex pfizer pfizer Animal Health pharmajet pharmaq pharmathene pharmexa pharmsynthez philip Morris Products ploughshare Innovations ppd preclin Biosystems presido Pharmaceuticals prevtec Microbia probiogen profectus Biosciences prokarium protein Potential protein Sciences protherics psioxus Therapeutics public Health Agency Of Canada purdue Research Foundation qiagen Infectious Vaccines Partnering Terms and Agreements
  15. 15. radboud University Nijmegen Medical Centre ragon Institute rapid Micro Biosystems ratio receptor Logic redbiotec regenx Biosciences replikun Biotech research Council Of Norway rhapsody Biologics riboxx Pharmaceuticals roche romark Laboratories rovi Pharmaceuticals sabin Vaccine Institute saic-frederick sanaria sanofi-aventis sanofi-pasteur sanofi sanofi Pasteur Kk saskatchewan Research Council scancell scarab Genomics schering-plough scigen scripps Research Institute seattle Biomed seek select Vaccines selecta Biosciences sentry Biopharma sepragen serum Institute Of India shanghai Bravobio shanghai Centers For Disease Control And Prevention shantha Biotechnics shenzhen Neptunus Interlong Bio-technique shionogi siga Technologies sinobiomed sinovac Beijing sinovac Biotech Infectious Vaccines Partnering Terms and Agreements
  16. 16. sk Chemicals skystar Biopharmaceutical small Business Innovation Research soligenix sorrento Therapeutics southern Research Institute sri International stabilitech statens Serum Institute stellar Biotechnologies sumagen swiss Tropical And Public Health Institute symphony Dynamo synthetic Genomics Vaccines syntiron synvolux Therapeutics taiwan Cobia takeda Pharmaceutical talecris Biotherapeutics tapimmune tasly Pharmaceuticals tb Alliance td Vaccines technology Strategy Board technovax telormedix temasek Life Sciences terumo tetragenetics the International Aids Vaccine Initiative the Qater Foundation tianjin Cansino Biotechnology tno Pharma top Institute Pharma torii Pharmaceutical transgene trius Therapeutics tuberculosis Vaccine Initiative tulane University uk Government uk Hiv Vaccine Consortium umn Pharma uniformed Services University Of The Health Sciences Infectious Vaccines Partnering Terms and Agreements
  17. 17. uniquest united Biomedical united Nations united Nations Children Fund united States Agency For International Development universidad De Los Andes university Of Adelaide university Of Birmingham university Of British Columbia university Of California, Davis university Of California university Of Canberra university Of Chicago university Of Colorado university Of Connecticut university Of Copenhagen university Of Guelph university Of Kansas university Of Maryland university Of Maryland Biotechnology Institute university Of Maryland School Of Medicine university Of Maryland Ventures university Of Massachusetts university Of Massachusetts Medical School university Of Medicine And Dentistry Of New Jersey university Of Melbourne university Of Miami Miller School Of Medicine university Of Michigan university Of Minnesota university Of New Mexico university Of North Carolina university Of Oxford university Of Pennsylvania university Of Pittsburgh university Of Queensland university Of Rochester university Of Rouen university Of Texas university Of Texas At El Paso university Of Texas Medical Branch university Of Utah university Of Washington university Of Wisconsin Infectious Vaccines Partnering Terms and Agreements
  18. 18. us Army us Army Medical Research Institute Of Infectious Diseases us Government vabiotech vaccibody vaccine And Gene Therapy Institute Of Florida (vgti-fl) vaccine Technologies vakzine Projekt Management vandalia Research vaxdesign vaxent vaxgen vaxin vaxinnate vet Cure Pharma vgx Pharmaceuticals vibalogics vical vichem Chemie victorian College Of Pharmacy viral Genetics virbac virexx virginia Commonwealth University virogen virosome Biologicals virostatics vitamfero vivaldi Biosciences vivalis wageningen University walter And Eliza Hall Institute walter Reed Army Institute Of Research wellcome Trust wistar Institute wittycell world Bank world Health Organization wyeth xcellerex xiamen University xoma xtl Biopharmaceuticals Infectious Vaccines Partnering Terms and Agreements
  19. 19. yokohama City University ypsomed yunnan Walvax Biotech zydus Cadila 6.3. By Deal Type asset Purchase assignment bigpharma Outlicensing co-development collaborative R&d co-market contract Service co-promotion crada cross-licensing development distribution equity Purchase evaluation grant joint Venture licensing litigation manufacturing manufacturing - Oem marketing material Transfer option promotion research settlement spin Out sub-license supply technology Transfer termination warranty 6.4. By Stage Of Development discovery formulation marketed Infectious Vaccines Partnering Terms and Agreements
  20. 20. phase I phase Ii phase Iii preclinical regulatory 6.5. By Infectives Therapy Area 6.5. By Vaccine And Adjuvant Technology Area vaccines adjuvant chapter 7 –partnering Resource Center 7.1. Online Partnering 7.2. Partnering Events 7.3. Further Reading On Dealmaking appendices appendix 1 – Deal Type Definitions about Wildwood Ventures current Partnering current Agreements recent Report Titles From Currentpartnering order Form – Therapy Reports ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Infectious Vaccines Partnering Terms and Agreements
  21. 21. Website: http://www.researchmoz.us/ Infectious Vaccines Partnering Terms and Agreements

×